The global prevalence of fungal diseases has escalated in the last several decades. Currently, it is estimated that fungi infect 1.7 billion people annually and result in 1.5 million deaths every year 1 . Deaths due to fungal infections are increasing, with mortality often exceeding 50%, further increasing to 100% if treatment is delayed 1 . Despite these staggering figures, the contribution of fungal infections to the global burden of disease remains under-recognised.
In Australia, over a 5-year period fungal infections cost
Australia an estimated $583 million Resistance to every class of antifungal drugs has been described and for some drug classes is extremely common 4, 5 .
More than 90% of all reported fungal deaths result from species that belong to one of three genera: Candida, Aspergillus and . Candida auris is an emerging fungal pathogen that has intrinsic multi-drug resistance. Since first emerging in 2009, C. auris has spread across five continents, including Australia, and resulted in a number of nosocomial outbreaks 6, 7 .
Cryptococcosis, caused by Cryptococcus neoformans and Cryptococcus gattii, is the most common invasive fungal disease globally, at one point with an estimated >1M life-threatening infections per year 1 . C. neoformans, isolated from soil or bird excrement, has a worldwide distribution and predominantly causes infections in immunocompromised individuals. C. gattii is isolated from eucalyptus and other trees, so has a more restricted distribution, and causes infections largely in immunocompetent individuals 8 .
Aspergillus species commonly cause invasive pulmonary aspergillosis in neutropenic patients, transplant recipients and in patients on immunosuppression (e.g. corticosteroids). Aspergillus species are found worldwide and are common in the environment resulting in continuous lung exposure 1 . The most common species are in the A. fumigatus complex, but A. flavus, A. niger, A. terreus and A. nidulans also cause infections in humans.
Antifungal drugs and emerging resistance
There are four main classes of antifungal drugs: polyenes, azoles, allylamines and echinocandins ( Figure 1 , Table 1 ). Polyenes (e.g. 13 . In a recent United States retrospective study acquired fluconazole resistance was reported in 19% of C. albicans infections 13 . At present, resistance to azoles is uncommon in Australia but may be increasing; a recent review of candidemia in Australia showed 16.7% of C. tropicalis isolates are resistant to both fluconazole and voriconazole 23 . A major concern is the emergence of infections caused by Candida species other than C. albicans, such as C. auris that has intrinsic multi-drug resistance. . Echinocandins inhibit ß1,3-glucan synthase (FKS1/2) to prevent the synthesis of ß1,3-D-glucan in the fungal cell wall. Azoles and allylamines inhibit lanosterol 14a-demethylase and squalene epoxidase, respectively, to inhibit the formation of ergosterol in the cell membrane. Polyenes bind to ergosterol in the cell membrane, causing pores to form and membrane leakage. In Focus
The first few instances of azole resistance in A. fumigatus were reported in the USA and Europe in the late 1980s and 90s in association with long-term antifungal treatment (extensively reviewed by Meis et al.
25
). Since then, the prevalence of resistant isolates has increased and has been found in patients who have not received azole treatment. The acquisition of resistance in patients who have not received azole treatment has led to the hypothesis that resistance can also be gained from the agricultural use of azoles 17 . In 1999, the prevalence of azole-resistant
A. fumigatus in The Netherlands was 12.8% but current incidence is 20% and resistance has now been reported in 11 different countries 5, 26 .
Molecular mechanisms of antifungal drug resistance
The emergence of antifungal drug resistance can occur due to changes in the genome [9] [10] [11] . On exposure to azole antifungal drugs, In A. fumigatus, the most common mechanism of azole resistance occurring within a host involves mutations in the cyp51A (ERG11) gene, which prevent the azole from binding to the heme molecule 16, 25 . In contrast, A. fumigatus resistant clinical strains acquired from the environment most commonly possess a duplication of a 34 bp tandem repeat in the promoter region of cyp51A, combined with a specific substitution that causes overexpression of the gene 5, 18 . These mutations confer multi-drug resistance and have been found to be correlated with exposure to agricultural azoles in the environment 16, 17 .
In comparison to resistance to azoles, almost nothing is known about the mechanisms that give rise to resistance to polyenes in The role of mutation rate in accelerating the emergence of resistance
Recent studies in C. glabrata and C. neoformans have revealed that a proportion of clinical isolates possess an elevated mutation rate (a 'mutator' phenotype), which can contribute to the rapid emergence of spontaneous antifungal drug resistance via increasing the opportunity for selectively advantageous mutations to occur 28, 29 .
Initial studies showed that 55% of C. glabrata clinical isolates contain non-synonymous variation in the MSH2 gene, which encodes a component of mismatch DNA repair 28 . The presence of non-synonymous variation in MSH2 correlated with multi-drug resistance 28 . C. glabrata clinical isolates possessing non-synonymous variation in MSH2 have now been detected in clinical populations in many parts of the world with varying prevalence (North America 55%; India 69%; France 44%; Korea 65%) [30] [31] [32] . However, there is not always an obvious correlation with drug resistance. In addition, an assessment of mutation rate was not performed in these studies, leading to the criticism that the variation in Clinical isolates of C. neoformans with non-synonymous variation in MSH2 have also been identified 29, 34 . These isolates exhibit a mutator phenotype and an increase in the emergence of spontaneous fluconazole and amphotericin B resistance 29 . Deletion of MSH2 in both C. glabrata and C. neoformans results in high levels of spontaneous resistance to multiple types of antifungals 28, 29 .
Conclusions
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